APA (7th ed.) Citation

V, R., M, M., M, V., S, M., N, J., M, K., . . . GC, H. (2026). Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease. Frontiers in immunology, 17, 1843217. https://doi.org/10.3389/fimmu.2026.1843217

Chicago Style (17th ed.) Citation

V, Raguraman, Mysinger M, Verma M, Mohiyuddin S, Jabbour N, Kesler M, Joshi T, Palaniyandi S, and Hildebrandt GC. "Targeting Bruton Tyrosine Kinase with Acalabrutinib Attenuates Murine Sclerodermatous Chronic Graft Versus Host Disease." Frontiers in Immunology 17 (2026): 1843217. https://doi.org/10.3389/fimmu.2026.1843217.

MLA (9th ed.) Citation

V, Raguraman, et al. "Targeting Bruton Tyrosine Kinase with Acalabrutinib Attenuates Murine Sclerodermatous Chronic Graft Versus Host Disease." Frontiers in Immunology, vol. 17, 2026, p. 1843217, https://doi.org/10.3389/fimmu.2026.1843217.